Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 14/20 | 0.57 |
| ▸ | EGFR | P00533 | 11/20 | 0.57 |
| ▸ | KDR | P35968 | 10/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.57 |
| ▸ | ABL1 | P00519 | 8/20 | 0.57 |
| ▸ | HCK | P08631 | 8/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.57 |
| ▸ | MTOR | P42345 | 8/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.57 |
| ▸ | EPHB4 | P54760 | 8/20 | 0.57 |
| ▸ | PRKDC | P78527 | 8/20 | 0.57 |
| ▸ | PI4KB | Q9UBF8 | 8/20 | 0.57 |
| ▸ | ITK | Q08881 | 2/20 | 0.56 |
| ▸ | LCK | P06239 | 5/20 | 0.53 |
| ▸ | TEK | Q02763 | 4/20 | 0.53 |
| ▸ | BTK | Q06187 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1497588 | 0.96 | SRC (0.59) | SRCEGFRKDRPIK3CDABL1 | |
| SCHEMBL1497592 | 0.96 | SRC (0.59) | SRCEGFRKDRPIK3CDABL1 | |
| SCHEMBL2397532 | 0.86 | SRC (0.63) | SRCEGFRKDRPIK3CDABL1 | |
| SCHEMBL2397534 | 0.86 | SRC (0.63) | SRCEGFRKDRPIK3CDABL1 | |
| SCHEMBL12265366 | 0.82 | SRC (0.65) | SRCEGFRKDRPIK3CDABL1 | |
| SCHEMBL1497692 | 0.78 | ITK (0.65) | SRCEGFRKDRPIK3CDABL1 | |
| SCHEMBL12265364 | 0.78 | SRC (0.63) | SRCEGFRKDRPIK3CDABL1 | |
| SCHEMBL27604491 | 0.76 | SRC (0.76) | SRCEGFRKDRPIK3CDABL1 | |
| SCHEMBL6431852 | 0.75 | LCK (0.78) | SRCEGFRKDRABL1HCK | |
| SCHEMBL6431851 | 0.75 | LCK (0.78) | SRCEGFRKDRABL1HCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2011031896-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | SRC 128/4885EGFR 580/4885KDR 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.